- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Embolization of uterine fibroids beats surgery
Lower costs, speedier recovery, and reduced pain give uterine artery embolization an edge over surgery for fibroid treatment, according to a multicenter trial that examined the relative merits of the two methods.
Lower costs, speedier recovery, and reduced pain give uterine artery embolization an edge over surgery for fibroid treatment, according to a multicenter trial that examined the relative merits of the two methods.
Researchers in the Randomized Trial of Embolization versus Surgical Treatment for Fibroids (REST), including 27 U.K. hospitals, assessed quality of life up to one year post-treatment for 157 women involved in the study who had been randomized to embolization or surgery (hysterectomy or myoectomy). They found that women who had embolization-costing about $1700 less than surgery-reported significantly less pain after their procedures, had much shorter hospital stays, were able to return to work and other activities more quickly, and had fewer post-treatment major adverse events than those who underwent surgery (NEJM 2007;356[4]:360-370).
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
Ultrasound Device Garners FDA De Novo Nod for Kidney Stone Clearance
November 14th 2024Emerging research demonstrated that the Stone Clear device, which facilitates post-lithotripsy clearance of kidney stone fragments, led to a 70 percent lower risk of relapse in comparison to observation in a control group.
